Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My email to Steve:
Hi Steve,
I just wanted to reach out today and again as I have before, express my frustration along with other shareholders in the daily manipulation happening with your guys stock. Every day on the Level II, OTCX plays endless games literally walking the price up or down to whatever that broker feels like. Every long term investor has seen this action endlessly, and now therefore have eliminated any desire to buy more shares, hence the complete lack of buying pressure lately.
You guys said you hired ShareIntel to find out where this manipulation has been coming from, yet not one single update has been given since, when it seems there has been plenty of time to at least develop a case on ShareIntels side. It seems like more and more longterm investors, including myself are starting to feel as if this was just a smokescreen of sorts, and are loosing confidence in a big way with this manipulation. I truly hope you are expressing to Alan how important it is to issue an update on this, even if the investigation isn't complete, what you guys will plan to do with the information you receive and what not. Although updates on everything else you guys have going on is awesome, it seem the only news that can bring back some buying pressure and confidence here is one that shows Endonovo's legitimacy in tackling this daily, constant manipulation and staying much more transparent with shareholders throughout this process.
I really hope you can do everything in your power as Vice President of Investor Relations to demonstrate to upper management how important of an issue this is to many of the roughly 350 investors of Endonovo.
Andrew's response to me today:
Thank you for your interest in Endonovo.
I received the below email which you had some questions regarding Endonovo.
I would like to express to you that I understand your frustration and am pleased to reply to your questions and suggestions regarding stock manipulation.
As you know, Endonovo retained Shareintel to research and monitor the trading activity in ENDV. This is an ongoing process that Shareintel is conducting. At this time, the company prefers not to make an official statement regarding the matter.
Please note, ENDV NOT making an official statement is not a 'smokescreen' or plan to frustrate shareholders. Based on the past findings and current and continued monitoring by Shareintel, it would be best for Endonovo to continue to gather information and then in conjunction with Shareintel and/or ENDV lawyers and/or S.E.C. and/or FINRA and/or other entities and governing bodies make decisions regarding next steps to be considered and taken.
The monitoring of trading activity is a process and not one that can have a final determination and or plan of action in a short period of time.
So am I technically allowed to post a copy of an email just sent to me by Andrew, or are there rules regarding that? I just got a response about ShareIntel i feel you guys would like to hear.
What is interesting is that I sent my email only to Steve yesterday, but today I received a reply only from Andrew.
From having talked to Steve multiple times through email and phone over the past year+ I can already say that the way Andrew addresses shareholders seems to be much more professional. Looking forward to this new IR contact.
Did anyone get a reply?? lol
Just sent a nice but serious toned, lengthy email myself describing my complete and utter frustration with the daily manipulation and lack of updates from ShareIntel. Lets do this
Im awaiting a call back to address this. I have confirmed on March 14th directly from the T/A that the O/S was 327,299,922. Now the 10k as of Friday (3 weeks later) is 341,345,596. That’s 14,045,674 shares added, over 4.5 million a week, simultaneously while they decided to gag the T/A.
Good bid support, lets see those shares on the ask get stolen from the owners, and hopefully slowly stop letting them do whatever they want here
My guess is that if we are getting some big news relating to financing and the ending of this agreement with Eagle which is tomorrow, (being Saturday) We see it mid way through next week, and hopefully we see Monday or Tuesday without those 1-2k ask slaps by Mann. Its still in my best beliefs that they cant release anything huge news wise without having a day break in his buys on the day it seems the PR is submitted. Most of the PR’s have followed this pattern.
Interesting. Tried calling transfer agent just now for updated O/S. I can no longer get that info over the phone. I was told the company has now directed shareholders to view this number via the OTC Markets page, as of about 3 weeks ago. And on that website, it says the current number is 324,851,484, which is lower than what it was a week or two ago.
New twitter post out an hour or so ago. The article was posted 5 days ago.
link: http://www.alleywatch.com/2018/03/where-we-are-investing-now-neuroscience/amp/?__twitter_impression=true
Something quite interesting I just noticed, not sure if anyone else did as well who follows Endonovo on Twitter, but I don't think I have ever seen a post get more than 20 or so likes, as it has always seemed there Twitter posts barely get noticed...
The tweet 6 days ago with the link to the article mentioning us, "Healthcare Companies Capitalizing on a Resurgent Biotech Industry" has 79 likes, seems like it has received much more notice than anything else posted from them on Twitter. I also remember seeing it at 20 or so a few days a go. Just an observation. I would love to slowly see their Twitter become more popular and get more attention, definitely a step in the right direction.
Interested to see when we see it, last year it didn’t come until mid April
What do you mean other shares hitting the market? The only convertible notes out there right now are from Eagle. In my opinion thats a weak excuse. Have you ever reached out to management? Give that a try with all those concerns and then if you don’t like what you hear from them, I can accept that.
It is just Eagle. I confirmed this a couple days ago. How about you hit IR with all those concerns. The more shareholders that raise concerns to them, the more pressure they have to give more updates.
Had a conversation with INVESTOR RELATIONS yesterday.
1) I expressed concern obviously about the share price, dilution, and how we can feasibly expect an up-list without a R/S this year, as they stated they wanted to do in the 2018 expectations.
- The general idea was that up-listing isn't going to happen overnight, and definitely will not happen if the time is not right. From the second I began the conversation, he expressed his disappointment in the share price. It seems it is still in their best interest to only up-list when things are looking different. Obviously thats a hard sight to envision right now with the daily dilution, and he wasn't able to share much more on this besides that things are progressing and that they are in the best position yet as a company. If you wanna hear his take on that, please reach out to him, thats the general theme I gathered.
2) I asked why the Tear Sheet is not up to date with accurate O/S.
- He said that the tear sheet is managed by a third party company that updates the investor portion of their website. He said he would reach out to them about this and would follow up with me. When talking about this as well, he did confirm that the only convertible notes out there are Eagle.
3) I confirmed that Mann's purchases are coming directly from his own wallet and in no way any funds come from the money raised by the company.
4) No updates on "relevant scientific meeting" that was stated in 10/13/17 PR for preclinical post MI-remodeling data. Also asked whats next for this part of the pipeline, in which he wasn't able to tell me any new info either besides what they originally stated.
5) No updates on ShareIntel, it sounds like they have received much interest about this recently and he has passed the concerns forward, but had nothing to share at the time.
6) No updates on SofPulse sales other than what's been stated, but they believe this revenue stream will be huge for their company.
Discussed a few other things with him but these were the main points. From my take on things, It sounds that they are just as frustrated about the PPS as us, believe they are unfairly valued, and still believe there are good things in store, and definitely positive updates to come. I think the biggest thing with this stock is everyone's timeframe and expectations. Ive always had a longterm mindset here, and my biggest concern that goes hand in hand with that is the fear of a R/S one day out of the blue, which it sounds is the last thing they want to do. As long as that remains the same, I personally am fine waiting longer for rewards to be gained here. Yes its frustrating and it sucks but an arbitrary opportunity is an arbitrary opportunity. The point is, we know we are undervalued here, and we know one day, the right kind of news, such as buying back of Eagle convertible notes or big SofPulse sales or partnership opportunities will make this thing run. Even if they just got tired one day and sold the company for 0.25 a share, Id still be a very happy camper. Point is, Endonovo is definitely worth more than their current share price, and I definitely believe there are better days for us to come.
And lastly, my closing thoughts, don't sit here and talk down on management without at least reaching out to them first. It's one thing to raise concerns, and another to continuously ridicule them without at least hearing their perspective on things. I just wanted to give a little insight into what was told to me, as I feel other longs concerns are consistent with mine. This is my fourth time talking to Steve since I became a shareholder here over a year ago. Any shareholder with questions of their own should reach out to him, he has always been very open to scheduling time to talk through any questions one may have.
Don't know why the heck this got deleted the first time, got reviewed and still deemed off topic so lets try this again. Cheers.
This was one of the 7-8 questions I have for Steve, I ended up postponing the call, Ive been too busy with class this week, hopefully will get on the phone with him tomorrow or Friday AM and then let you guys know a little about what I hear.
Really quick this morning I did call the T/A and current O/S is: 327,299,922
Uplisting* excuse me
Thats perfect, i was actually going to ask if anyone had questions aside from mine which i will post later, in class right now. Main idea is dilution and how we can expect uplifting this year w/o a R/S, the scientific meeting they said they would attend and a couple other things
Dont want to jinx anything as I always seem to do, but first day in a while with no Mann buys so far. Usually he has bought by this time in the day. Also we haven’t seen a T-Trade the last two trading days. Pair that with their updated O/S that I got from the T/A yesterday (324,851,484) that has only increased around 1 million in the last 9-10 days, definitely a slower rate than usual. I also reached out to Steve yesterday via email to see when is best to talk on the phone and run a bunch of questions by him, and said this week is not good and way too busy. Hopefully something big is in the works
The shares Mann buys, the”insider buying” you are referring about are bought with his own money and not any kind of money coming from the company or dilution. Confirmed from the company long ago. Yes, Mann seems to of done well for himself as he seems to have a lot of extra money around to keep buying shares, but that’s not the same as a president of a company diluting their stock, and using proceeds to buy shares for themselves, which is illegal.
Thats quite the unusual set of T-Trades just a couple minutes ago. Executed 2 cents above our close price. Don’t think we’ve ever seen that here before
New tweet highlighting EFFECT Trial
https://twitter.com/Endonovo/status/969288141197606912
If we don’t see a Form 4 today or tomorrow, Id say a PR next week is hopefully more likely based on previous PR patterns. But then again Im probably jinxing it, that always seems to happen lol
No I don’t unfortunately. I will start though. I will reach out to IR to see why the number is not more up to date on their tear sheet. Numbers this morning from the TA
O/S: 323,896,529
Float: 163,771,644
Im confused on the actual O/S. On Endonovo’s website on their Tear Sheet that apparently is updated every day, the O/S is 305.2 million currently.
Just food for thought. If we make it through today with no sign of a Mann purchase (none yet), and also without a t-trade hopefully (today would be 5th day in a row), that makes me wonder if we are in store for a PR In the next few days about something to do with this. It seems the last few PR's Mann has taken a day break in buying before submitting the PR and has been consistent in buying at least once a day. Almost as if he's giving us longs a little hint lol
Agreed Sello, nice posts, I'm right there with ya. And I too will be crushed if we see a damn T tomorrow LOL
Honestly that was incredibly noticeable just now, I hope those are the things ShareIntel is seeing. Best set of ask slaps to start a day in a long time and then stopped right in its tracks
I have noticed that as well, definitely has me interested.
Well thats an unexpected PR. I like it, lets see if that does anything to the price. Either way, happy to hear they are listening to us. Definitely still believe management cares about us
I think it's interesting that we haven't seen a form 4 in a while. Should of had one from purchases last week from the 5th - 8th already, the last form 4 had purchases through last Monday the 4th.
If you have been somewhat smart about averaging down, this is the opposite. Sit back and wait for the day to come. Every day that goes by doesn't change how much of an arbitrary opportunity this is. When my average sits around these prices, i truly feel there isn't much to worry about here. This will at the very least get up to the price targets in due time, with the potential to go much higher.
I think we all need to be on Mann watch the next few days, another day or two without any purchases from the big guy and I think we are looking at a possible big material event on the near horizon. Just my opinion, but its been a while where we have seen a complete absence of him like Wednesday, with the imminent release of the rest of the data along with other material events that could happen, along with very strong technicals (thanks midas for continuing to point those out) I think we could be in store for a fruitful few weeks before Christmas. Its my bday next week too, hoping Endonovo gives me a nice little surprise this year :) happy thanksgiving guys, cheers
No mann ask slaps today as well, kind of fun if that continues through EOD. Little extra speculation here, as others have said, I get more excited when I don't see him buy. Quick question, Is the OTC open on Friday?
Not to be condescending but I'm just going to list parts of the article where products and devices are mentioned If you read past the first paragraph, you will see that "devices and products" are what are mainly highlighted in this new RMAT designation... i barely even see where drugs are mentioned besides in the beginning... I think Endonovo's "product or device" whatever you want to call it, fits in very nicely with what is being mentioned in this article...
Today the U.S. Food and Drug Administration announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.
The framework – outlined in a suite of four guidance documents – builds upon the FDA's existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products.
As such, it has presented unique challenges to researchers, health care providers, and the FDA as we seek to provide a clear pathway for those developing new therapies in this promising field, while making sure that the FDA meets its obligation to ensure the safety and efficacy of the medical products that patients rely upon.
With the policy framework the FDA is announcing today, we're adopting a risk-based and science-based approach that builds upon existing regulations to support innovative product development while clarifying the FDA's authorities and enforcement priorities.
As this field advances, the FDA has noted that there are a growing number of regenerative medicine products subject to FDA premarket authorization. These guidance documents will help explain how the FDA will provide a risk-based framework for its oversight. The policy framework defines how we intend to take action against unsafe products while facilitating continued innovation of promising technologies.
Going forward, the FDA will apply a risk-based approach to enforcement, taking into account how products are being administered as well as the diseases and conditions for which they are being used. This risk-based approach allows product manufacturers time to engage with the FDA, as to determine if they need to submit a marketing authorization application and, if so, submit their application to the FDA for approval.
The first draft guidance, which builds off the regenerative medicine provisions in the 21st Century Cures Act, addresses how the FDA intends to simplify and streamline its application of the regulatory requirements for devices used in the recovery, isolation, and delivery of regenerative medicine advanced therapies (RMATs), including combination products. The guidance specifies that devices intended for use with a specific RMAT may, together with the RMAT, be considered to comprise a combination product.
The second draft guidance describes the expedited programs that may be available to sponsors of regenerative medicine therapies, including the new Regenerative Medicine Advanced Therapy (RMAT) designation created by the 21st Century Cures Act, Priority Review, and Accelerated Approval. In addition, the guidance describes the regenerative medicine therapies that may be eligible for RMAT designation – including cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, as well as gene therapies that lead to a durable modification of cells or tissues (including genetically modified cells).
"In addition to clarifying some of the more complex areas of the regulations, we have taken meaningful new steps to encourage and expedite the development of innovative therapies."
That's what I had running through my mind. Boy would that be absolutely killer news. Not counting on anything, but when you put things together, it isn't really far fetched at all. Very excited for the coming weeks and months here. Cheers enjoy the rest of your weekend guys.
Recent FDA news out on regenerative medicine a couple days ago. I'm honestly surprised nobody has posted about this yet, unless I missed it. This is straight from PR Newswire posted yesterday. More details I believe on the FDA's website.
FDA announces comprehensive regenerative medicine policy framework
Today the U.S. Food and Drug Administration announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.
The framework – outlined in a suite of four guidance documents – builds upon the FDA's existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products. Further, two of the guidance documents propose an efficient, science-based process for helping to ensure the safety and effectiveness of these therapies, while supporting development in this area. The suite of guidance documents also defines a risk-based framework for how the FDA intends to focus its enforcement actions against those products that raise potential significant safety concerns. This modern framework is intended to balance the agency's commitment to safety with mechanisms to drive further advances in regenerative medicine so innovators can bring new, effective therapies to patients as quickly and safely as possible. The policy also delivers on important provisions of the 21st Century Cures Act.
"We're at the beginning of a paradigm change in medicine with the promise of being able to facilitate regeneration of parts of the human body, where cells and tissues can be engineered to grow healthy, functional organs to replace diseased ones; new genes can be introduced into the body to combat disease; and adult stem cells can generate replacements for cells that are lost to injury or disease. This is no longer the stuff of science fiction. This is the practical promise of modern applications of regenerative medicine," said FDA Commissioner Scott Gottlieb, M.D. "But this field is dynamic and complex. As such, it has presented unique challenges to researchers, health care providers, and the FDA as we seek to provide a clear pathway for those developing new therapies in this promising field, while making sure that the FDA meets its obligation to ensure the safety and efficacy of the medical products that patients rely upon. Alongside all the promise, we've also seen products marketed that are dangerous and have harmed people. With the policy framework the FDA is announcing today, we're adopting a risk-based and science-based approach that builds upon existing regulations to support innovative product development while clarifying the FDA's authorities and enforcement priorities. This will protect patients from products that pose potential significant risks, while accelerating access to safe and effective new therapies."
The framework includes two final guidance documents and two draft guidance documents.
New Final Guidance Documents
The two final guidance documents clarify the FDA's interpretation of the risk-based criteria manufacturers use to determine whether a product is subject to the FDA's premarket review.
The first guidance provides greater clarity around when cell and tissue-based products would be excepted from the established regulations if they are removed from and implanted into the same individual within the same surgical procedure and remain in their original form. The second final guidance helps stakeholders better understand how existing regulatory criteria apply to their products by clarifying how the agency interprets the existing regulatory definitions "minimal manipulation" and "homologous use." As this field advances, the FDA has noted that there are a growing number of regenerative medicine products subject to FDA premarket authorization. These guidance documents will help explain how the FDA will provide a risk-based framework for its oversight. The policy framework defines how we intend to take action against unsafe products while facilitating continued innovation of promising technologies.
To accomplish this goal, the guidance document has clarified the FDA's view of "minimal manipulation" and "homologous use." These are two concepts that are defined in current regulation to establish the legal threshold for when a product is subject to the FDA's premarket approval requirements. By further clarifying these terms in the final guidance, the FDA is applying a modern framework for its oversight. Under the new policy, in order to allow manufacturers of products time to comply with the requirements, for the first 36 months following issuance of the final guidance document the FDA intends to exercise enforcement discretion for certain products that are subject to the FDA's premarket review under the existing regulations, but are not currently meeting these requirements. The FDA does not intend to exercise such enforcement discretion for those products that pose a potential significant safety concern. Going forward, the FDA will apply a risk-based approach to enforcement, taking into account how products are being administered as well as the diseases and conditions for which they are being used. This risk-based approach allows product manufacturers time to engage with the FDA, as to determine if they need to submit a marketing authorization application and, if so, submit their application to the FDA for approval.
New Draft Guidance Documents
The two draft guidances provide important information to help spur development and access to innovative regenerative therapies. The first draft guidance, which builds off the regenerative medicine provisions in the 21st Century Cures Act, addresses how the FDA intends to simplify and streamline its application of the regulatory requirements for devices used in the recovery, isolation, and delivery of regenerative medicine advanced therapies (RMATs), including combination products. The guidance specifies that devices intended for use with a specific RMAT may, together with the RMAT, be considered to comprise a combination product.
The second draft guidance describes the expedited programs that may be available to sponsors of regenerative medicine therapies, including the new Regenerative Medicine Advanced Therapy (RMAT) designation created by the 21st Century Cures Act, Priority Review, and Accelerated Approval. In addition, the guidance describes the regenerative medicine therapies that may be eligible for RMAT designation – including cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, as well as gene therapies that lead to a durable modification of cells or tissues (including genetically modified cells).
"As a molecular and cell biologist and physician, it has been exciting to witness the approval of the first two gene therapies in the U.S. this year. Given the great opportunities that the field of regenerative medicine presents, we have undertaken a rigorous process to clarify our regulations that included solicitation of public input, and I believe today marks a significant step forward for all stakeholders," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research. "In addition to clarifying some of the more complex areas of the regulations, we have taken meaningful new steps to encourage and expedite the development of innovative therapies."
I am not the most knowledgable on the different FDA designations and what Endonovo could apply for, but can't help but be extremely intrigued reading about this and the RMAT designation, as well as just seeing how the FDA is further embracing the wave of regenerative medicine with open arms. Can't help but think we are in store for some big things here. Whether management runs with this all the way or takes a buyout offer down the road before anything gets to market, either way it is hard to not be bullish here. The potential here is huge. Some people may disagree but I literally don't care if this is a 10 year+ investment for me. If this truly goes the direction many of us possibly think, some will look very foolish selling for a couple dollars with the potential here. Again, time will tell and anything can happen, but I am very excited reading something like this. Cheers fellow longs enjoy your weekend!
Lol the stock market is the transfer of impatient money to patient money. Do what you want man, but I feel confident holding this through a stock market crash due to the tech. This could easily pull a JAZZ. $0.90, 7 years later, $ 150 per share. Only the true longs killed it there.
I know an R/S isn't what anyone wants, including myself, but not all
R/S's are always that bad in the right circumstances. If they needed one to get the price from 0.25 to 4 dollars for example, being a 1/16 split of shares, but then a couple years down the road, their price is triple digits (I always look at JAZZ as an ex. of what can happen here potentially), then we would all still be very wealthy here. Just food for thought. So much can happen here I think people need to give management a little more credit sometimes for everything they seem to have going on the back end. And everytime i have quesions, IR is very responsive. But anyone that likes to post here about their frustrations with management but refuses to reach out to them to get what their input and questions answered is a pretty cowardly move. PR's cost money. Money that can be used to many other things they have going on in my opinion. Again just a long term shareholders opinion here. I don't care if I hold this for 10 years to fully reek the reward of what we have here. Good things should happen in due time. Patience seems like it could pay off big time here.
You know these guys will do everything in their power to create a downtrend to pick up shares at the cheapest price possible.
Unlike true longs that wont bash the heck out of this company even if they want to average down more, like myself. Id rather slap the ask at these cheap prices every day and keep my average around 0.04, knowing that in a couple years this investment should pay off in huge proportions. 750k and going strong. People boast about their profits going from .02 - .09 when in reality the real longs that hold through the waves and are on board when this gets a major valuation change will be some of happiest ones out there. Oh yeah and we wont have to pay out the govt. on those short term gains either. Such an easy hold here. A little tipsy so excuse me if I made any grammar mistakes, but its fun looking at this board sometimes and seeing people try to paint this as a scam or a bad investment to get cheaper shares. Well have a major "i told you so" moment hopefully sooner than later to all these guys. And to everyone who's "buying in the .02's and selling in the .09's, good for you. Just hope you don't get caught with no shares when that major change in valuation happens.
Looks like we have a base at 0.04 with these buys coming in, honestly thought the first 30 minutes would be worse. Almost a million volume already too
Quarterly report released 12 minutes ago